159 related articles for article (PubMed ID: 21647142)
1. ERasing breast cancer resistance through the kinome.
Johnson AB; O'Malley BW
Nat Med; 2011 Jun; 17(6):660-1. PubMed ID: 21647142
[No Abstract] [Full Text] [Related]
2. A CUE hints at tumor resistance.
Thomas C; Gustafsson JA
Nat Med; 2011 Jun; 17(6):658-60. PubMed ID: 21647141
[No Abstract] [Full Text] [Related]
3. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.
Pan X; Zhou T; Tai YH; Wang C; Zhao J; Cao Y; Chen Y; Zhang PJ; Yu M; Zhen C; Mu R; Bai ZF; Li HY; Li AL; Liang B; Jian Z; Zhang WN; Man JH; Gao YF; Gong WL; Wei LX; Zhang XM
Nat Med; 2011 Jun; 17(6):708-14. PubMed ID: 21572428
[TBL] [Abstract][Full Text] [Related]
4. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
5. Pak up your breast tumor--and grow!
Jordan VC
J Natl Cancer Inst; 2006 May; 98(10):657-9. PubMed ID: 16705113
[No Abstract] [Full Text] [Related]
6. Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
Xiong R; Patel HK; Gutgesell LM; Zhao J; Delgado-Rivera L; Pham TND; Zhao H; Carlson K; Martin T; Katzenellenbogen JA; Moore TW; Tonetti DA; Thatcher GRJ
J Med Chem; 2016 Jan; 59(1):219-237. PubMed ID: 26681208
[TBL] [Abstract][Full Text] [Related]
7. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.
Farahmand L; Mansouri S; Jafarbeik-Iravani N; Teymourzadeh A; Majidzadeh-A K
Recent Pat Anticancer Drug Discov; 2018; 13(3):302-307. PubMed ID: 29512469
[TBL] [Abstract][Full Text] [Related]
8. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
9. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
10. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
Schiff R; Osborne CK
Breast Cancer Res; 2005; 7(5):205-11. PubMed ID: 16168139
[TBL] [Abstract][Full Text] [Related]
11. Role of endothelin-1 in tamoxifen resistance: Mechanism for a new possible treatment strategy in breast cancer.
Namazi S; Rouhani Fard SA; Abedtash H
Med Hypotheses; 2008; 70(1):109-11. PubMed ID: 17576039
[TBL] [Abstract][Full Text] [Related]
12. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
13. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
14. Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges.
Barua D; Gupta A; Gupta S
Cancer Lett; 2020 Aug; 486():29-37. PubMed ID: 32446861
[TBL] [Abstract][Full Text] [Related]
15. DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression.
Liu J; Li J; Li P; Jiang Y; Chen H; Wang R; Cao F; Liu P
J Cell Mol Med; 2019 Jan; 23(1):512-521. PubMed ID: 30450766
[TBL] [Abstract][Full Text] [Related]
16. Estrogen can restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance.
Mansouri S; Farahmand L; Hosseinzade A; Eslami-S Z; Majidzadeh-A K
Biomed Pharmacother; 2017 Sep; 93():1320-1325. PubMed ID: 28747013
[TBL] [Abstract][Full Text] [Related]
17. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
McClaine RJ; Marshall AM; Wagh PK; Waltz SE
Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
[TBL] [Abstract][Full Text] [Related]
18. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.
Rayala SK; Kumar R
Biomed Pharmacother; 2007 Aug; 61(7):408-11. PubMed ID: 17604944
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the use of neoadjuvant endocrine therapy.
Agrawal LS; Mayer IA
Curr Oncol Rep; 2015 Jul; 17(7):33. PubMed ID: 26008918
[TBL] [Abstract][Full Text] [Related]
20. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
